Start NAMENDA to slow symptom progression— clinical evidence confirms cognitive, functional, behavioral, and global benefits in moderate and severe Alzheimer's disease.
NAMENDA targets a different pathway
NAMENDA is the first and only NMDA-receptor antagonist for the treatment of moderate to severe Alzheimer's disease. Learn more about its unique mechanism of action
Proven efficacy with combination therapy
For patients taking AChEIs, NAMENDA offers proven efficacy in memory and language, daily functioning, and can improve or delay behavioral symptoms. Read moreEffective as first-line treatment
For newly diagnosed moderate or severe patients and those who do not tolerate AChEIs, NAMENDA offers proven efficacy in cognition and day-to-day function. Read moreProven efficacy in severe Alzheimer's disease
In severe patients, NAMENDA was shown to improve the ability to perform daily activities, which may help reduce care dependence. Read moreCaregiver benefits
NAMENDA significantly reduces monthly caregiving time. Read moreNAMENDA: Safe with excellent tolerability
NAMENDA has been used by over 2 million patients worldwide.Safety profile in clinical trials Read more Low potential for drug-drug interactions Read more
Starting your patients on NAMENDA
NAMENDA is easy to start with and easy to stay with. Read more about dosing and administrationImportant Safety Information
NAMENDA® (memantine HCl) is indicated for the treatment of moderate to severe Alzheimer's disease. NAMENDA has been used by more than 2 million people worldwide.NAMENDA is contraindicated in patients with known hypersensitivity to memantine HCl or any excipients used in the formulation. The most common adverse events reported with NAMENDA vs placebo (≥5% and higher than placebo) were dizziness, confusion, headache, and constipation. In patients with severe renal impairment, the dosage should be reduced.
See Full Prescribing Information